

# Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Brad Spellberg<sup>1,2</sup> and Benjamin A. Lipsky<sup>3,4</sup>

<sup>1</sup>Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, and <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, California; <sup>3</sup>VA Puget Sound Health Care System, and <sup>4</sup>University of Washington, Seattle

**The standard recommendation for treating chronic osteomyelitis is 6 weeks of parenteral antibiotic therapy. However, oral antibiotics are available that achieve adequate levels in bone, and there are now more published studies of oral than parenteral antibiotic therapy for patients with chronic osteomyelitis. Oral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associated with intravenous catheters and is generally less expensive, making it a reasonable choice for osteomyelitis caused by susceptible organisms. Addition of adjunctive rifampin to other antibiotics may improve cure rates. The optimal duration of therapy for chronic osteomyelitis remains uncertain. There is no evidence that antibiotic therapy for >4–6 weeks improves outcomes compared with shorter regimens. In view of concerns about encouraging antibiotic resistance to unnecessarily prolonged treatment, defining the optimal route and duration of antibiotic therapy and the role of surgical debridement in treating chronic osteomyelitis are important, unmet needs.**

Chronic osteomyelitis is an infection of bone that does not result from acute hematogenous seeding or penetrating injury and usually occurs by contiguous spread and has been present for several weeks. Perhaps the earliest known case of chronic osteomyelitis dates to the Permian era, in an unfortunate dimetrodon that developed infection in a fractured spinal shaft [1]. This 250 million-year-old case highlights 3 of the problems that remain common when managing chronic osteomyelitis: (1) the diagnosis was established only after bone (or rather fossil) biopsy; (2) no cultures were performed to define the etiologic organism; and (3) treatment (if any) was probably delayed and certainly ineffective.

In the antibiotic era, chronic osteomyelitis remains difficult to treat and has a high rate of relapse after

apparently successful treatment [2–4]. Indeed, case reports have described relapses of osteomyelitis up to 80 years after the initial presentation [5–8]. These relapses are probably due to bacterial evasion of host defenses by hiding intracellularly and as nonreplicating persisters within biofilm [9]. Because of these concerns, clinicians often treat chronic osteomyelitis with antibiotic therapy that is parenteral, high dose, and prolonged. This standard recommendation derives largely from the belief that it takes 3–4 weeks for infected bone to revascularize as well as from experience treating children with acute osteomyelitis. It was codified by a seminal case series by Waldvogel et al [10–12] in 1970. The authors stated that “osteomyelitis is rarely controlled without the combination of careful, complete surgical debridement and prolonged (4–6 weeks) parenteral antibiotic therapy at high dosage.” However, this case series was retrospective and uncontrolled, and it included a heterogeneous patient population, and parenteral penicillin was the predominant antibiotic administered.

What have we learned about treating chronic osteomyelitis in the past few decades? Previous reviews of this topic have concluded that available literature is inadequate to determine the best agent, route, or duration

Received 31 August 2011; accepted 29 September 2011; electronically published 12 December 2011.

Correspondence: Brad Spellberg, MD, Division of General Internal Medicine, Harbor-UCLA Medical Center, 1124 West Carson St., Liu Vaccine Building, Torrance, CA 90502 (bspellberg@labiomed.org).

**Clinical Infectious Diseases** 2012;54(3):393–407

© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/cir842

**Table 1. Bone Penetration of Parenteral Antibiotics: Data From Clinical Studies**

Drug (Dose)	Patients, No.	Serum Level, Mean, $\mu\text{g/mL}$	Bone Level, Mean, $\mu\text{g/g}$	Ratio of Bone/Serum Levels, %	Reference
Agents Predominantly Used to Treat Gram-Positive Infections					
Oxacillin (2 g)	NA	NA	NA	10 <sup>a</sup>	[16]
Ampicillin (2 g)	20	NA	12	17 <sup>b</sup>	[17]
Sulbactam (1 g)			7	12 <sup>b</sup>	
Ampicillin (1 g)	40	NA	20	33 <sup>b</sup>	
Sulbactam (0.5 g)			5	17 <sup>b</sup>	[18]
Cefazolin (1 g)	35	80	10 (knee), 30 (hip)	13 (knee), 37 (hip)	[19]
Cefazolin (1 g)	20	45	8	18	[20]
Cefazolin (1 g)	17	52	6	11.5	[21]
Cefazolin (2 g)	6	98	15	15	
Cefazolin (1 g)	48	NA	6	7.5 <sup>b</sup>	[22]
Cefazolin (1–2 g)	16	25–216	3–10	<10	[23]
Vancomycin (1 g)	14	22 (medullary)	2.3 (medullary)	10	[24]
		22 (cortical)	1.1 (cortical)	5	
		16.8 (infected)	3.6 (infected)	21	
Daptomycin (6 mg/kg)	4	73	5	7	[25]
Agents Predominantly Used to Treat Gram-Negative Infections					
Ceftriaxone (1 g)	13	104	20 $\pm$ 6	19	[26]
Ceftriaxone (2 g)	40	130	19 $\pm$ 7 (medullary)	15	[27]
			6.5 $\pm$ 1.6 (cortical)	5	
Ceftriaxone (2 g)	42	NA	17 $\pm$ 9 (medullary)	NA	[28]
			3 $\pm$ 0.7 (cortical)	NA	
Ceftazidime (2 g)	10	150	5 (ischemic legs)	3	[29]
Ceftazidime (1 g)	43	NA	20	27 <sup>c</sup>	[30]
Imipenem (500 mg)	6	NA	6 (infected)	48 <sup>c</sup>	[31]
Cefepime (2 g)	10	73 $\pm$ 24	74 $\pm$ 16 (cancellous)	100	[32]
			68 $\pm$ 12 (cortical)	87	
Imipenem (1 g)	16	NA	4	16 <sup>c</sup>	[33]
Imipenem (500 mg)	10	13	2.6 (infected)	20	[34]
Meropenem (500 mg)	15	30	5.75	17	[35]
Piperacillin (3 g)/tazobactam (0.375 g)	10	NA	NA	20/25 <sup>d</sup>	[36]
Piperacillin (4 g)	NA	200	15	7.5	[37]
Piperacillin (2 g)	18	95	5	5	[38]

Abbreviation: NA, not applicable.

<sup>a</sup> Full article not available in English; the abstract reported a 10% ratio.

<sup>b</sup> Assuming peak ampicillin serum levels of 120 and 60  $\mu\text{g/mL}$  at doses of 2 and 1 g, respectively [39, 40], peak sulbactam levels of 60 and 30  $\mu\text{g/mL}$  at doses of 1 and 0.5 g [39, 40], and a peak cefazolin level of 80  $\mu\text{g/mL}$  at a dose of 1 g [41].

<sup>c</sup> Assuming peak serum levels of 75  $\mu\text{g/mL}$  for ceftazidime [42] and 12.5  $\mu\text{g/mL}$  and 25  $\mu\text{g/mL}$  for imipenem at doses of 500 and 1000 mg, respectively [43, 44, 45].

<sup>d</sup> As specified in the study abstract.

of antibiotic therapy [13–15]. Undeterred, we set out to review studies published since 1970 in an attempt to address 4 fundamental questions regarding treatment of chronic osteomyelitis in adults: (1) Are certain antibiotic agents preferred choices? (2) Are oral regimens acceptable for selected cases? (3) For how long should antibiotic therapy be given? and (4) Is surgical debridement always necessary for cure? We searched PubMed and ScienceDirect for the term “osteomyelitis” from 1970 to 2011, and EBSCO, Web of Science, and Google Scholar for any types of studies on treatment of chronic

osteomyelitis in adults. We reviewed all articles if they, or at least their abstracts, were in English.

## PHARMACOLOGY OF OSTEOMYELITIS THERAPY

### Parenteral Antibiotic Agents

$\beta$ -Lactam antibiotics (penicillins, cephalosporins, and carbapenems) penetrate bone at levels ranging from ~5% to 20% of those in serum (Table 1). Nevertheless, because serum levels of

parenterally delivered  $\beta$ -lactam antibiotics are so high, absolute bone levels likely exceed target minimum inhibitory concentrations (MICs) of etiologic bacteria in most cases. In contrast, because serum levels of oral  $\beta$ -lactam agents are <10% of those of parenteral agents, oral dosing is unlikely to achieve adequate bone levels.  $\beta$ -lactam penetration is higher in infected than in uninfected bone [31, 33, 34], but it is markedly decreased in patients with peripheral vascular disease [29, 46] and is probably low in sequestra.

Similar to  $\beta$ -lactam antibiotics, vancomycin penetrates bone poorly [24] (Table 1). However, when serum levels of vancomycin were >35  $\mu$ g/mL, its penetration of sternal bone (~30% of serum concentrations) was better than in axial skeletal bone [47, 48]. Daptomycin also penetrates bone relatively poorly (Table 1), but levels are probably high enough to exceed the target MICs for bacteria in bone [25, 49].

### Oral Antibiotic Agents

Recent studies demonstrate that oral antibiotics can achieve levels in bone that exceed MICs of targeted organisms (Table 2). In particular, fluoroquinolones, linezolid, and trimethoprim have been found to achieve bone concentrations at ~50% of serum [52, 53, 55] (Table 2). Although the sulfamethoxazole component of trimethoprim-sulfamethoxazole (TMP-SMX) has poorer penetration (10%–20%), its serum concentrations are 20-fold higher than those of trimethoprim, so its bone concentrations generally exceed the MICs of susceptible organisms. Because TMP-SMX exhibits concentration-dependent killing [88–90], higher doses (ie, 7–10 mg/kg trimethoprim, or 2 double-strength tablets twice per day) may result in greater efficacy when treating chronic osteomyelitis. The lack of a fixed 1:5 ratio of concentrations of trimethoprim and sulfamethoxazole at the site of infection does not hinder their synergy [91].

Other orally available agents to which many community-associated strains of methicillin-resistant *Staphylococcus aureus* (MRSA) are susceptible are doxycycline and clindamycin [92–95]. Doxycycline penetrates, and discolors, teeth [96] and bone, but concentrations range from as low as 2% in axial skeletal bone [62, 63] to as high as 86% in mandibular bone [61] (Table 2). Clindamycin reliably penetrates bone at levels of approximately 40%–70% of serum [64–66] (Table 2), and its achievable bone levels should exceed the MICs of susceptible MRSA isolates.

An oral antibiotic option for treatment of anaerobic osteomyelitis is metronidazole, which penetrates bone at concentrations approximating those in serum [67, 68] (Table 2). In case reports, metronidazole has been found to cure anaerobic osteomyelitis, including as salvage therapy after failure of clindamycin or cephalosporin therapy [97–100]. Rifampin also achieves concentrations in bone near, or exceeding, those in serum [69, 82, 83, 101] (Table 2). Because serum concentrations of rifampin increase dramatically at doses >450 mg/d [102, 103], prescribing

600 mg once daily should suffice. Finally, both fusidic acid [70, 71, 104] and fosfomycin [72] penetrate bone extremely well, at concentrations in excess of target MICs (Table 2).

In summary, oral options for the treatment of chronic osteomyelitis based on pharmacokinetic considerations include fluoroquinolones, TMP-SMX, or fosfomycin for susceptible gram-negative bacilli, and TMP-SMX, clindamycin, and linezolid for susceptible gram-positive infections. Rifampin and fusidic acid are reasonable adjunctive agents for combination therapy.

## ANIMAL MODELS OF CHRONIC OSTEOMYELITIS

Standard models of chronic staphylococcal osteomyelitis include those in which infection is induced in long bones of rabbits and rats [2]. In such models, in vitro kill curves do not reliably predict in vivo efficacy. For example, in both models, rifampin was more active in vivo than clindamycin, azithromycin, vancomycin, trimethoprim, and ciprofloxacin, and it was synergistic in vivo with each of these agents as well as with cephalothin, despite being either indifferent or antagonistic to all of them in vitro [82, 101, 105]. In addition, ciprofloxacin monotherapy had minimal in vivo effect when treating infection caused by *S. aureus* strains susceptible to ciprofloxacin in vitro [82]. Thus, rifampin exhibits synergistic activity in vivo with myriad antibiotics, and clinicians should be cautious about using ciprofloxacin monotherapy to treat osteomyelitis caused by *S. aureus*, regardless of the MIC of the isolate.

## NONRANDOMIZED CLINICAL TRIALS

### Parenteral Therapy

In nonrandomized studies of adults with chronic osteomyelitis, 4–6 weeks of parenteral  $\beta$ -lactam antibiotic therapy has cured 60%–90% of cases (Table 3). The varying cure rates may be related to variable diagnostic criteria, use of concomitant surgical debridement (specifically reported in only 2 studies [107, 108]), or duration of follow-up. In multiple studies, the cure rates of infections caused by *Pseudomonas* were lower than those for other pathogens [108, 109, 112].

Vancomycin achieves low cure rates for chronic osteomyelitis [117, 121, 122]. In patients receiving outpatient parenteral antibiotic therapy of osteomyelitis, treatment of *S. aureus* infection with vancomycin (compared with  $\beta$ -lactam agents) had an odds ratio (OR) for recurrence of 2.5 by multivariate analysis [121, 122]. Other independent risk factors for recurrence included the presence of diabetes mellitus (OR, 1.9), peripheral vascular disease (OR, 7.9), and infection with *Pseudomonas* (OR, 2.2).

In a salvage study of patients with MRSA osteomyelitis that had failed to respond to previous therapy, all 9 patients who were treated with daptomycin had clinical resolution of their

**Table 2. Bone Penetration of Antibiotics With High Oral Bioavailability: Data From Clinical Studies**

Drug	Patients, No.	Dose	Route	Serum Level, Mean (Range), $\mu\text{g/mL}$	Bone Level, Mean (Range), $\mu\text{g/g}$	Serum-Bone Ratio, %	Reference
Ciprofloxacin	7	500 mg	Oral	1.4 (0.4–2)	0.4 (0.2–0.9)	30	[50]
	7	750 mg	Oral	2.6 (0.9–4)	0.7 (0.2–1.4)	27	
	6	500 mg	Oral	2.0 (0.9–3)	0.7 (0.2–1.4) <sup>a</sup>	35	
	4	750 mg	Oral	2.9 (1–6)	1.4 (0.6–2.7) <sup>a</sup>	48	
Ciprofloxacin	20	200 mg	Intravenous	NA	2 (medullary)	66	[51]
					1.4 (cortical)	47 <sup>b</sup>	
Ciprofloxacin	15	200 mg	Intravenous	NA	0.1–0.9	3–30 <sup>b</sup>	[52]
Levofloxacin	9	500 mg	Intravenous	8	6 (medullary)	75	[53]
					3 (cortical)	38	
Levofloxacin	12	500 mg	Intravenous	7.5	7.4 (medullary)	99	[54]
					3.9 (cortical)	50	
Enoxacin	24	400 mg	Oral or	2.4	0.9	37.5	[55]
			Intravenous		1.3 <sup>b</sup>	55	
Moxifloxacin	10	400 mg	Intravenous	4.9	1.9 (medullary)	39	[56]
					1.3 (cortical)	27	
	10	400 mg	Oral	3.7	1.8 (medullary)	49	
					1.6 (cortical)	43	
Linezolid	13	600 mg	Oral	NA	4	40 <sup>c</sup>	[57]
Linezolid	12	600 mg	Oral	NA	9	51 <sup>c</sup>	[58]
Linezolid	10	600 mg	Oral	23	8.5	37	[59]
TMP-SMX	14	1 DS tablet twice daily for 2 d	Oral	7.4/143	3.7/19	50/15	[60]
Doxycycline	6	200 mg	Intravenous	NA	2.6	86 <sup>a</sup>	[61]
Doxycycline	25	200 mg	Intravenous	NA	0.2	6 <sup>a</sup>	[62]
Doxycycline	34	200 mg	Intravenous	6	0.13	2	[63]
Clindamycin	13	600 mg	Intravenous or intramuscular	NA	5	67 <sup>a</sup>	[64]
Clindamycin	27	300 mg	Intramuscular	7.33	2.63	40	[65]
Clindamycin	23	600 mg	Intravenous	8.5	3.8	45	[66]
Metronidazole	16	500 mg	Intravenous	NA	14	100 <sup>a</sup>	[67]
Metronidazole	17	1500 mg	Intravenous	34	27	79	[68]
Rifampin	32	300 mg	Intravenous	2	5 (1.4–8.8)	>100 <sup>c</sup>	[69]
Fusidic acid in infected bone <sup>d</sup>	15	500 mg 3 times daily	Oral	NA	7.3 (1.7–14.9)		[70]
					9.8 (3.4–14.8)		
Fusidic acid in uninfected bone	9	500 mg 3 times daily for 5 d	Oral	27 (2–109)	12 (1–40)	44	[70]
					21 (2–75)	47	
					25 (3–79)	93	
	14	500 mg 3 times daily for >10 d	Oral	27 (3–59)	25 (3–79)	93	
Fusidic acid	30	2 or 3 g/d	Oral	15–210	1.5–54	NA	[71]
Fosfomycin	19	10 g once, then 5 g 3 times daily	Intravenous	NA	13.5 (uninfected)	NA	[72]
					42.1 (infected) <sup>d</sup>		
Fosfomycin	9	100 mg/kg	Intravenous	377 $\pm$ 73	96 $\pm$ 15	25	[73]

Abbreviations: NA, not applicable; TMP-SMX, trimethoprim-sulfamethoxazole.

<sup>a</sup> Levels in infected (osteomyelitic) bone after debridement.

<sup>b</sup> Assuming peak serum levels of 3  $\mu\text{g/mL}$  for ciprofloxacin [74], 20  $\mu\text{g/mL}$  for linezolid [75, 76], 3  $\mu\text{g/mL}$  for doxycycline [77], 8  $\mu\text{g/mL}$  for clindamycin [66, 78, 79], and ~14  $\mu\text{g/mL}$  for metronidazole [80, 81].

<sup>c</sup> Concordant animal data [79, 82, 83, 84, 85, 86, 87].

<sup>d</sup> Infected bone refers to levels measured in osteomyelitic bone that was debrided.

**Table 3. Cure Rates in Nonrandomized Clinical Trials of Parenteral Agents for Chronic Osteomyelitis With or Without Infected Prosthesis in Adults**

Drug	Dose (Duration)	Follow-up	Cure, <sup>a</sup> No. of Patients (%)	Comment	Reference
Cefazolin	2–4 g/d (mean, 35 d)	Mean, 34 mo	15/16 (94)	4/5 diabetic foot infections cured, all with debridement	[23]
Cefotaxime	1 g/8 h (duration unclear)	0–17 mo	24/27 (89)	Cure defined as disease “arrested”	[106]
Cefotaxime	2–16 g/d (mean, 23 d)	?	25/32 (78)	Cure with surgery in 21/24, without surgery in 4/8	[107]
Imipenem	0.1–1 g/6 h (mean, 5 wk)	Mean, 11 mo	20/34 (59)	<i>Pseudomonas</i> main cause of failure: 10/14 cured	[108]
Ceftazidime	2 g/12 h (2–16 wk)	>12 mo	9/15 (60)	12 cases caused by <i>Pseudomonas</i>	[109]
Cefotaxime	2 g/6 h (mean, 40 d)	6 mo	40/55 (73)	...	[110]
Aztreonam	2 g/6 h (14–55 d)	4–18 mo	11/11 (100)	All infections due to gram-negative rods	[111]
Aztreonam	2 g/8 h (mean, 40 d)	Mean, 6 mo	13/18 (72)	All due to <i>Pseudomonas</i>	[112]
(Cefsulodin or piperacillin or imipenem) + (ofloxacin or pefloxacin or ciprofloxacin)	Varying doses ( $\geq$ 4 mo)	Mean, 3 y	11/15 (73)	All due to <i>Pseudomonas</i>	[113]
Ampicillin-sulbactam	1.5 g/6 h (mean, 41 d)	?	42/49 (86)	All patients diabetic; 14 patients had amputations	[114]
Ticarcillin-clavulanate	9–12 g/d (mean, 6 wk)	?	39/50 (78)	...	[115]
Cefepime + (ofloxacin or ciprofloxacin)	Cefepime: 2 g twice daily (4 wk); ofloxacin: 200 mg 3 times daily (3–9 mo); ciprofloxacin: 500–750 mg twice daily (3–9 mo)	?	22/28 (79)	Mixture of chronic osteomyelitis and prosthetic implant infections; quinolones given intravenously at first and then by mouth	[116]
Vancomycin	Variable dosing (mean, 6 wk)	?	44/81 (54)	62 patients underwent debridement; 30 had infected prostheses, 27 had removal	[117]
$\beta$ -Lactam or vancomycin	Variable for $\beta$ -lactam; vancomycin: 1 g/12 h (mean, 66 d for MRSA, 55 d for MSSA)	>12 mo	30/35 (86)	Relapses: 0/15 patients treated with rifampin vs 5/20 treated without rifampin; all started with intravenous therapy; many received subsequent oral therapy with various agents	[118]
Daptomycin	6 mg/kg/d	?	8/9 (89)	Infection resolved in all patients, relapse in 1 patient; salvage therapy	[119]
Daptomycin	6 mg/kg/d (median, 38 d)	Mean, 9 wk	16/25 (64)	16 resolved, 8 improved	[49]
Daptomycin	Variable dosing (mean, 35 d)	Mean, 76 d	42/67 (63)	Failures more likely with no debridement (24% vs 5%) and with doses <4 mg/kg/d (35% vs 12%)	[120]

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *S. aureus*.

<sup>a</sup> Definitions of cure varied among the trials.

infection by the end of therapy, but 1 patient subsequently relapsed [119]. Larger retrospective studies of daptomycin treatment of chronic osteomyelitis have reported cure rates of 65%–75% [49, 120]. Case reports suggest the potential for quinupristin-dalfopristin and tigecycline to cure chronic osteomyelitis, but clinical data are limited [123–126].

### Oral Therapy: Fluoroquinolones

There are more studies of fluoroquinolones for treating chronic osteomyelitis than of all other antibiotic classes (Table 4). Cross-study comparisons are difficult because of the varied criteria for enrollment, utilization of debridement, antibiotic dosing regimens, duration of follow-up, and definitions of cure. Nevertheless, we draw several general inferences from these studies.

1. Most studies reported cure rates of 60%–80% [129, 138, 139].
2. Cure rates were similar to debridement rates (when reported), but because none of the studies specifically reported cure rates of patients who did and did not undergo debridement, the benefit of debridement can only be inferred.
3. The majority of failures occurred in patients infected with *Pseudomonas*, and to a lesser extent, patients infected with *S. aureus*.
4. Therapy was typically given for 12–16 weeks, and at doses higher than those used for most other infections (eg, ciprofloxacin at  $\geq 1500$  mg/d), but it is not possible from the available data to conclude that this high-dose and prolonged treatment is necessary.

### Oral Therapy: Other Agents

Although it should never be used alone for treating osteomyelitis, several reports have shown that rifampin improves treatment outcomes when used in combination with other antibiotics (Table 4). Norden et al [101] added rifampin to therapy with a  $\beta$ -lactam, doxycycline, or an aminoglycoside in 14 patients, most of whom had had osteomyelitis for  $>15$  years and in whom multiple prior treatment attempts had failed. Overall, 50% were cured, and patients in whom treatment failed were all infected with gram-negative bacilli resistant to the non-rifampin agent. In another study of patients with *S. aureus* osteomyelitis, there were no relapses among 15 patients in whom rifampin was added to treatment with various other antibiotic agents compared with 5 relapses among 20 patients who did not receive adjunctive rifampin [118]. Finally, adjunctive rifampin improved cure rates of prosthetic joint infections in 2 recent studies [143, 144].

A large compassionate-use data set demonstrated that linezolid treatment cured 60% of the 89 patients with chronic osteomyelitis [145]. In several case reports, clindamycin therapy successfully eradicated anaerobic osteomyelitis [153–155]. Likewise, among 12 patients with chronic (primarily staphylococcal)

osteomyelitis treated with clindamycin at very low doses (75–150 mg/6 h), 5 patients were cured and another 5 showed substantial improvement [146].

TMP-SMX is second only to ciprofloxacin in the number of published studies of its effectiveness for treatment of chronic osteomyelitis. Saengnipanthkul et al [148] reported a 45% cure rate using standard dose TMP-SMX (1 double-strength tablet twice daily) to treat 66 patients with chronic osteomyelitis, only 55% of whom underwent surgical debridement. Cure rates based on surgical debridement were not separately reported. In contrast, Sanchez et al [149] treated 27 patients with staphylococcal osteomyelitis (25 *S. aureus*) with a higher-than-usual dose of TMP-SMX (7 mg/kg/d of trimethoprim divided into 2 or 3 daily doses) along with rifampin for a mean of 5 weeks, in addition to surgical debridement. After follow-up of 6 months to 5 years, all of the patients were cured.

Javaloyas de Morlius et al [78] reported their results with treating 37 patients with 44 episodes of osteomyelitis, 34 of which were associated with an orthopedic implant. After a week of parenteral antibiotic therapy, the patients received a median of 10 weeks of oral treatment with TMP-SMX plus rifampin (23 patients), TMP-SMX alone (5 patients), or rifampin plus ciprofloxacin (7 patients). At 2 years of follow-up, all 10 patients who had their hardware removed were cured, compared with 18 of 24 patients (75%) in whom hardware was left in place.

Stein et al [150] prescribed TMP-SMX for 6–9 months to treat 39 patients with prosthetic devices infected with MRSA. The overall success rate was 67% in the intention-to-treat population and 87% in the per-protocol population (after exclusion of 9 patients who were unable to tolerate completing the treatment). Significantly more patients who had their infected prosthetics removed were cured compared with those who did not. Likewise, de Barros et al [84] treated 60 patients with chronic osteomyelitis with TMP-SMX for 6 months, along with appropriate surgical debridement; 59 (98%) were cured after 12–60 months of follow-up. Finally, Nguyen et al [151] reported that either TMP-SMX (8 mg/kg/d) or linezolid combined with rifampin cured 79%–89% of patients with infected orthopedic implants or chronic osteomyelitis. Taken together, these data support the efficacy of high-dose TMP-SMX, the importance of concurrent surgical debridement, and the possible benefit of adjunctive rifampin therapy and prolonged therapy when treating chronic osteomyelitis, especially in patients with an associated infected implant.

Consistent with their excellent bone penetration, both fosfomycin [72, 152] and fusidic acid [156, 157], the latter preferably in combination with another anti-staphylococcal agent, have also demonstrated efficacy in treating chronic osteomyelitis. Others have summarized results of the numerous published case series describing fusidic acid combination therapy for osteomyelitis [156].

**Table 4. Cure Rates in Nonrandomized Clinical Trials for Oral Treatment of Chronic Osteomyelitis With or Without Infected Prosthesis in Adults**

Drug	Dose (Duration) <sup>a</sup>	Follow-up	Cure, <sup>b</sup> % (No. of Patients)	Comment	Reference
Fluoroquinolones					
Ciprofloxacin	500–750 mg twice daily (3–4 mo)	1 y	33 (12/36)	All cured patients had foreign material removed; 1/3 underwent debridement	[127]
Ciprofloxacin	750 mg twice daily (3–4 mo)	6 mo	91 (21/23)	Cure defined as resolution or improvement	[128]
Ciprofloxacin	750 mg twice daily (3 mo)	7–21 mo	65 (13/20)	Only 7/13 <i>Pseudomonas</i> infections cured; all debrided	[129]
Ciprofloxacin	750 mg twice daily (2–4 mo)	1–17 mo	77 (17/22)	4 patients who failed therapy with <i>Pseudomonas</i> ; 20 debrided	[130]
Ciprofloxacin	750 mg twice daily (1–6 mo)	0–22 mo	48 (14/29)	7/12 <i>Pseudomonas</i> and 4/9 <i>Staphylococcus aureus</i> infections cured	[131]
Ciprofloxacin or nafcillin, clindamycin, or gentamicin	750 mg by mouth twice daily (12–64 d) (ciprofloxacin); or varying doses and durations	25–39 mo	79 (11/14) for ciprofloxacin vs 83 (10/12) for intravenous therapy	Not randomized; patients were sequentially enrolled in the 2 arms	[132]
Ciprofloxacin	200 mg intravenous twice daily, then 750 mg by mouth twice daily	?	67 (6/9)	Unknown duration of treatment; 5/7 <i>Pseudomonas</i> infections cured	[133]
Ciprofloxacin	200 mg intravenous twice daily, then 750 mg by mouth twice daily	?	83 (10/12)	Unknown duration of treatment	[134]
Ciprofloxacin	500–1500 mg twice daily (0.5–18 mo)	?	68 (30/44)	<i>Pseudomonas</i> eradicated microbiologically in 20/28	[135]
Levofloxacin	500 mg/d	?	60 (9/15)	Failure of cure in 6 patients with <i>S. aureus</i> and 1 with <i>Pseudomonas</i> infection	[136]
Pefloxacin	400 mg/12 h intravenous for 4 doses, then 400 mg/12 h by mouth (3–6 mo)	?	76 (29/38)	All cured patients had foreign material removed; 1/3 underwent debridement	[137]
Ofloxacin	200 mg/8–12 h (3–6 mo)				
Ciprofloxacin	500–750 mg/12 h (3–6 mo)				
Ofloxacin	200 mg 3 times daily (4–6 wk)	>6 mo	85 (98/115)	Failure of cure in 3/15 patients with <i>Pseudomonas</i> and 5/74 with <i>S. aureus</i> infection; debridement in 113	[138]
Ciprofloxacin	750–1000 mg twice daily (3 mo)	12 mo	61 (19/31)	No benefit from higher dose; all had soft tissue, but not bone, debrided	[139] <sup>c</sup>
Ofloxacin + rifampin	Ofloxacin: 200 mg 3 times daily; rifampin: 300 mg 3 times daily (both, 6–9 mo)	>6 mo	71 (35/49)	All infections of prostheses	[140]
Levofloxacin + rifampin	Levofloxacin: 500 mg/d; rifampin: 600 mg/d (both, >6 wk)	>6 mo	72 (18/25)	All had prosthetic bone implants; mean duration of therapy, 5 mo for those cured and 2.6 mo for those without cure	[141]
Rifampin + (ofloxacin or fusidic acid)	Rifampin: 900 mg/d; ofloxacin: 200 mg 3 times daily; fusidic acid: 500 mg 3 times daily for 5 d, then twice daily (both, >6 mo)	Mean, 24 mo (range, 12–36 mo)	55 (11/20)	All patients had orthopedic implants, only 14 of which were removed; patients were assigned to treatment arm by year of birth (ofloxacin for even years, fusidic acid for odd years)	[142]

Table 4 continued.

Drug	Dose (Duration) <sup>a</sup>	Follow-up	Cure, <sup>b</sup> % (No. of Patients)	Comment	Reference
			50 (11/22)		
Other Agents					
Rifampin + various other antibiotics	600 mg/d (6 mo)	Variable	50 (7/14)	All cases refractory to prior therapy	[101]
Rifampin + quinolone vs other antibiotics	When used, rifampin at 20 mg/kg, divided into 2 daily doses (not to exceed 1800 mg/d)	Mean, 44 ± 32 mo	98 (37/39) vs 68 (40/59)	All patients had <i>S. aureus</i> prosthetic joint infections; 29 received rifampin in combination with nonquinolone antibiotics; in multivariate analysis, rifampin-quinolone combination had an odds ratio of 0.4 (95% CI 0.17–0.97) for failure	[143]
Rifampin + levofloxacin (prospective) vs historical cohort with variable antibiotics, without or with rifampin	When used, rifampin at 900 mg/d (3–6 mo)	?	93 (13/14) (prospective) vs 63 (34/56) (historical without rifampin) vs 68 (21/31) (historical with rifampin)	All had retained prosthetic joints; by multivariate analysis, hazard ratio for treatment failure was 1.0 for historical cohort without rifampin, 0.55 (95% CI 0.25–1.26) for historical cohort with rifampin, 0.11 (95% CI 0.01–0.84) for prospective rifampin cohort ( <i>P</i> = .03)	[144]
Linezolid	600 mg/12 h	?	60 (45/89)	Compassionate use program	[145]
Clindamycin	50–150 mg/6 h (mean, 16 wk)	Variable	42 (5/12)	...	[146]
TMP-SMX	1–2 DS tablet twice daily	?	83 (5/6)	No patients had debridement	[147]
TMP-SMX	1 DS tablet twice daily (4–8 wk)	11–70 mo	45 (30/66)	55% of patients had debridement	[148]
TMP-SMX + rifampin	TMP: 3.5 mg/kg twice daily; rifampin: 600–1200 mg/d (mean, 5 wk for both)	6 mo to 5 y	100 (27/27)	All patients had debridement	[149]
TMP-SMX with or without rifampin	DS tablet twice daily; rifampin: 300–450 mg twice daily (median, 10 wk for both)	2 y	82 (28/34)	10 patients had debridement, all of whom were cured	[78]
TMP-SMX	TMP: 5 mg/kg twice daily (6–9 mo)	24–75 mo	67 (26/39)	11 patients had device removed	[150]
TMP-SMX	Dose unclear (6 mo)	12–60 mo	98 (59/60)	All patients had debridement	[84]



Table 4 continued.

Drug	Dose (Duration) <sup>a</sup>	Follow-up	Cure, <sup>b</sup> % (No. of Patients)	Comment	Reference
(TMP-SMX or linezolid) + rifampin	TMP: 8 mg/kg; linezolid: 600 mg twice daily; rifampin: 10 mg/kg twice daily (all given intravenously for 1 wk and then by mouth)	≥12 mo	89 (37/41)	20 patients with chronic osteomyelitis and 56 with orthopedic implant infections; mean treatment durations were 15 wk (range, 1–53 wk) for TMP-SMX–based therapy and 18 wk (8–36 wk) for linezolid-based therapy; adverse event rates were similar (46% vs 43%), as were discontinuation rates (14% vs 21%)	[151]
Fosfomycin	10 g once, then 5 g 3 times daily	5–28 d	79 (29/38) 47 (29/60)	Outcome defined as “very good”; mean follow-up, 37 mo	[72]
Fosfomycin	4–8 g/d intravenous or by mouth		78 (29/37)	23 patients had debridement	[152]

Abbreviations: CI, confidence interval; DS, double-strength; TMP-SMX, trimethoprim-sulfamethoxazole.

<sup>a</sup> Drugs were administered orally unless otherwise specified.

<sup>b</sup> Definitions of cure varied among the studies.

<sup>c</sup> This was a randomized study of ciprofloxacin at 750 vs 1000 mg twice daily. Because no comparator therapy was used, it is included in the nonrandomized study category.

## Randomized Clinical Trials

There have been few randomized trials of systemic therapy for osteomyelitis in adults. A systematic review published in 2009 found only 8 small trials, with a total of 228 evaluable subjects [158]. A composite analysis of the 5 trials that compared oral with parenteral treatment found no significant difference in remission rate at ≥12 months of follow-up, but the rate of moderate or severe adverse events was significantly higher with parenteral than with oral agents (15.5% vs 4.8%, respectively).

Adjunctive rifampin therapy has been studied in 2 randomized clinical trials of patients with chronic osteomyelitis caused by *S. aureus* [159, 160] (Table 5). Summarizing their results, more patients who received rifampin in addition to other antibiotics were cured compared with those who did not (17 of 20 [85%] vs 12 of 21 [57%];  $P = .05$  by Fisher’s exact test), and no patient terminated therapy due to rifampin-related adverse effects. In another trial, Zimmerli et al [163] randomized patients with prosthetic devices infected with *Staphylococcus* spp. to receive either rifampin or placebo, plus ciprofloxacin, for 3–6 months. In the per-protocol population, cure rates were 100% for rifampin-treated versus 58% for placebo-treated patients ( $P < .02$ ). Of note, the causative pathogen in 4 of the 5 patients whose infection failed to respond to ciprofloxacin monotherapy developed resistance to ciprofloxacin.

Six studies randomized patients with chronic osteomyelitis to receive either an oral fluoroquinolone (ciprofloxacin in 3 [164–166], ofloxacin in 3 [167–169]) or standard intravenous therapy (Table 5). In all, cure rates were similar for those treated with oral and intravenous therapy. Finally, Euba et al [170] randomized 50 patients with chronic osteomyelitis caused by methicillin-sensitive *S. aureus* to treatment with intravenous cloxacillin or oral TMP-SMX plus rifampin for 8 weeks. All patients underwent surgical debridement, and 20 (40%) patients had prosthetic implants. At the end of therapy, cure rates were nearly identical for the 2 regimens (91% and 89%, respectively), as were the rates of antibiotic-related adverse events (3 in each arm). Furthermore, at median follow-up of 10 years (interquartile range, 4–13 years), the relapse rate was similarly low (10% and 11%, respectively). Among the 3 patients who relapsed on oral therapy, 2 had retained prosthetic material.

## CONCLUSIONS

Assessing treatments of chronic osteomyelitis is confounded by several factors, including the difficulty in diagnosing the condition or establishing a microbiological etiology, the presence of necrotic bone in most (and prosthetic implants in many) patients, and the lack of a consensus definition of cure. Nevertheless, we draw several conclusions from available published studies.

**Table 5. Cure Rates in Randomized Clinical Trials of Antibiotics for Chronic Osteomyelitis With or Without Infected Prosthesis in Adults**

Drug	Dose (Duration)	Follow-up	Cure, <sup>a</sup> % (No. of Patients)	Comment	Reference
Ceftazidime vs ticarcillin + tobramycin	Ceftazidime: 2 g/12 h intravenous; ticarcillin: 3 g/4 h intravenous; tobramycin: 1.5 mg/kg/8 h intravenous (mean, 35 d; range, 26–63 d)	2–31 mo	67 (6/9) vs 100 (9/9)	Open label; all patients had debridement	[161]
(Vancomycin or oxacillin) + (rifampin vs pyridium placebo)	Vancomycin: 1 g/12 h intravenous; oxacillin: 3 g/6 h intravenous; rifampin: 600 mg/d by mouth	?	90 (9/10) vs 62 (8/13)	Double-blind study	[159]
Nafcillin vs (nafcillin + rifampin)	Nafcillin: 20 mg/kg/4 h intravenous; rifampin: 600 mg/12 h by mouth (mean, 6 wk)	9–36 mo	80 (8/10) vs 50 (4/8)	Open label; 16 patients had debridement	[160]
Linezolid vs (ampicillin-sulbactam or amoxicillin-clavulonate)	Linezolid: 600 mg twice daily, by mouth or intravenous; ampicillin-sulbactam: 1.5–3 g/6 h intravenous; amoxicillin-clavulonate: 500–875 mg by mouth 2 or 3 times daily	?	61 (27/44) vs 69 (11/16)	Open label; part of larger trial of diabetic patients with soft-tissue infections; patients requiring >4 wk of therapy were excluded	[162]
Ciprofloxacin + (rifampin vs placebo)	Ciprofloxacin: 750 mg by mouth twice daily; rifampin: 450 mg by mouth twice daily (3–6 mo)	Median, 3 y	100 (12/12) vs 58 (7/12)	Double-blind study	[163]
Ciprofloxacin vs “appropriate antimicrobial therapy”	750 mg by mouth twice daily (treatment for ≥6 wk)	?	50 (7/14) vs 69 (11/16)	For patients infected with <i>Pseudomonas</i> , cure rate were 3/8 for ciprofloxacin vs 7/9 for comparator antibiotics	[164]
Ciprofloxacin vs ceftazidime	Ciprofloxacin: 200 mg intravenous twice daily, then 500 mg by mouth twice daily; ceftazidime: 2 g/12 h intravenous	?	67 (2/3) vs 100 (3/3)	Part of larger study of serious gram-negative infections; open label	[165]
Ciprofloxacin vs (ceftazidime or nafcillin + amikacin)	Ciprofloxacin: 750 mg by mouth twice daily; other antibiotics: ? doses (mean, 8 wk)	1 y	77 (24/31) vs 79 (22/28)	Open label; all patients had debridement	[166]
Ciprofloxacin vs lomefloxacin	Ciprofloxacin: 750 mg by mouth twice daily; lomefloxacin: 800 mg by mouth twice daily	Median, 8 mo (range, 0–36 mo)	40 (2/5)  71 (5/7)	Open label; 5 failures with ofloxacin were due to infections with <i>Pseudomonas</i> (n = 2) or <i>Staphylococcus aureus</i> (n = 3)	[166]
Ofloxacin vs (ceftazidime or cefazolin)	Ofloxacin: 400 mg by mouth twice daily (mean, 8 wk); ceftazidime: 2 g/12 h intravenous (mean, 4 wk); cefazolin: 1 g/8 h intravenous (mean, 4 wk)	Mean, 1.5 y	74 (14/19) vs 86 (12/14)	Open label; part of larger study of soft-tissue foot infections in diabetic patients	[167]
Ofloxacin vs ampicillin-sulbactam followed by amoxicillin-clavulonate	Ofloxacin: 400 mg by mouth twice daily; ampicillin-sulbactam: 1–2 g/6 h intravenous; amoxicillin-clavulonate: 500 mg by mouth 3 times daily	3–4 wk	39 (6/16) vs 20 (1/5)	Open label	[168]
Ofloxacin vs imipenem	Ofloxacin: 400 mg by mouth twice daily; imipenem: 500 mg/6 h intravenous	?	69 (11/16) vs 50 (8/16)	All patients had debridement	[169]
Cloxacillin vs (TMP-SMX + rifampin)	Cloxacillin: 2 g/4 h intravenous; TMP: 7–8 mg/kg by mouth twice daily; rifampin: 600 mg/d by mouth (8 wk)	Mean, 10 y	90 (19/21) vs 89 (24/27)	Open label; all patients had debridement	[170]

Abbreviation: TMP-SMX, trimethoprim-sulfamethoxazole.

<sup>a</sup> Definitions of cure varied by study.

First, oral antibiotic therapy with highly bioavailable agents is an acceptable alternative to parenteral therapy. The widely held preference for parenteral therapy for chronic osteomyelitis is based more on custom than evidence. There are actually fewer published studies of parenteral than oral therapy for osteomyelitis, and success rates are consistently similar for both routes. Furthermore, oral therapy is generally simpler for the patient, avoids risks associated with intravenous catheters, and is less expensive. Preferred oral agents, based on both pharmacokinetic and clinical data, include fluoroquinolones or TMP-SMX, which achieve high cure rates when administered for 8–16 weeks, particularly in the context of concomitant surgical debridement. We would like to see studies of shorter durations of treatment (eg, 4–6 weeks) to determine whether they produce similar results. It may be advisable to use higher-than-usual doses (eg, ciprofloxacin at 750 mg twice daily and TMP-SMX at 7–10 mg/kg/d of trimethoprim) when treating chronic osteomyelitis. Because gram-positive cocci have a high propensity to develop resistance during fluoroquinolone therapy [171], the reported relapses of staphylococcal osteomyelitis after ciprofloxacin or ofloxacin treatment are not surprising. Therefore, TMP-SMX and probably clindamycin are preferable for treating osteomyelitis caused by gram-positive cocci. Other options for selected cases could include linezolid or doxycycline, although toxicity with prolonged treatment limits use of the former agent, and no clinical data are available for the latter. For anaerobic osteomyelitis, oral metronidazole is the agent of choice, given its outstanding bone penetration and efficacy in case reports. Although the theory is still being debated, there is no evidence that bactericidal agents are superior to bacteriostatic in the treatment of osteomyelitis [172].

Second, adding rifampin to a variety of antibiotic regimens has been shown to improve the cure rates in: (1) animal models, (2) retrospective studies in humans, and (3) randomized clinical trials of chronic osteomyelitis and orthopedic implant infections. Hence, clinicians should consider adjunctive rifampin therapy (ie, combined with another active agent) for patients who are able to tolerate it and who do not require concomitant treatment with drugs with which it is likely to interact.

Third, clinicians must individualize the duration of antibiotic therapy based on the patient's clinical and radiographic response, with continued monitoring after cessation of therapy. No strong evidence supports the standard recommendation of 4–6 weeks of therapy after surgical debridement [4], nor is there evidence that more prolonged therapy further improves cure rates. Unfortunately, there are no well established markers of successful treatment and relapse rates remain substantial, even after prolonged antibiotic therapy. Defining the optimal duration of therapy for chronic osteomyelitis is an area of urgent need.

Fourth, surgical resection of necrotic and infected bone, in conjunction with antibiotic therapy, appears to increase the cure

rate of chronic osteomyelitis. However, not all cases of chronic osteomyelitis require surgical debridement for cure, and we need studies to clarify which may and which may not. We need comparative effectiveness studies to answer these and a number of other questions regarding therapy of chronic osteomyelitis.

## Note

**Potential conflicts of interest.** B. S. has received clinical trial grant/contract support from Gilead, Astellas, Novartis, and Cubist and consulting fees from GlaxoSmithKline, Pfizer, Basilea, The Medicines Company, Achaogen, Eisai, Meiji, and Polymedix. B. A. L. has received grant support or provided consultation to the following: Pfizer, Merck, Cubist, and Johnson & Johnson.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Moodie RL. Osteomyelitis in the Permian. *Science* **1921**; 53:333.
- Norden CW. Lessons learned from animal models of osteomyelitis. *Rev Infect Dis* **1988**; 10:103–10.
- Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. *N Engl J Med* **1980**; 303:360–70.
- Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? *Int J Infect Dis* **2010**; 14:e752–8.
- Al-Maiyah M, Hemmady MV, Shoaib A, Morgan-Jones RL. Recurrence of chronic osteomyelitis in a regenerated fibula after 65 years. *Orthopedics* **2007**; 30:403–4.
- Donati L, Quadri P, Reiner M. Reactivation of osteomyelitis caused by *Staphylococcus aureus* after 50 years. *J Am Geriatr Soc* **1999**; 47:1035–7.
- West WF, Kelly PJ, Martin WJ. Chronic osteomyelitis. I. Factors affecting the results of treatment in 186 patients. *JAMA* **1970**; 213:1837–42.
- Gallie WE. First recurrence of osteomyelitis eighty years after infection. *J Bone Joint Surg Br* **1951**; 33-B:110–1.
- Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis: why do antibiotics fail so often? *Postgrad Med J* **2000**; 76:479–83.
- Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. *N Engl J Med* **1970**; 282:198–206.
- Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). *N Engl J Med* **1970**; 282:260–6.
- Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. *N Engl J Med* **1970**; 282:316–22.
- Stengel D, Bauwens K, Sehoul J, Ekkernkamp A, Porzolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. *Lancet Infect Dis* **2001**; 1:175–88.
- Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? *Int J Infect Dis* **2005**; 9:127–38.
- Rod-Fleury T, Dunkel N, Assal M, et al. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. *Int Orthop* **2011**; 35:1725–31.
- Wewalka G, Ender M, Kraft A. Antibiotic concentrations in wound secretions and bone during the simultaneous administration of mezlocillin and oxacillin. *Infection* **1982**; 10(Suppl 3):S213–6.

17. Warnke JP, Wildfeuer A, Eibel G, Pfaff G, Klammer A. Pharmacokinetics of ampicillin/sulbactam in patients undergoing spinal micro-neurosurgical procedures. *Int J Clin Pharmacol Ther* **1998**; 36:253–7.
18. Wildfeuer A, Mallwitz J, Gotthardt H, et al. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery. *Infection* **1997**; 25:258–62.
19. Cunha BA, Gossling HR, Pasternak HS, Nightingale CH, Quintiliani R. Penetration of cephalosporins into bone. *Infection* **1984**; 12:80–4.
20. Polk R, Hume A, Kline BJ, Cardea J. Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion. *Clin Orthop* **1983**; 177:216–21.
21. Williams DN, Gustilo RB, Beverly R, Kind AC. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. *Clin Orthop* **1983**; 179:253–65.
22. Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS. Cefazolin concentrations in bone and synovial fluid. *J Bone Joint Surg Am* **1978**; 60:359–62.
23. Fass RJ. Treatment of osteomyelitis and septic arthritis with cefazolin. *Antimicrob Agents Chemother* **1978**; 13:405–11.
24. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. *Antimicrob Agents Chemother* **1988**; 32:1320–2.
25. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. *J Antimicrob Chemother* **2010**; 65:1252–7.
26. Lovering AM, Walsh TR, Bannister GC, MacGowan AP. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. *J Antimicrob Chemother* **2001**; 47:483–6.
27. Soudry B, Sirot J, Lopitiaux R, Dumont C, Delisle JJ, Parenton M. Diffusion of ceftriaxone in human bone tissue. *Pathol Biol (Paris)* **1986**; 34:859–62.
28. Scaglione F, De Martini G, Peretto L, et al. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. *Antimicrob Agents Chemother* **1997**; 41:2292–4.
29. Raymakers JT, Schaper NC, van der Heyden JJ, Tordoir JH, Kitslaar PJ. Penetration of ceftazidime into bone from severely ischaemic limbs. *J Antimicrob Chemother* **1998**; 42:543–5.
30. Leigh DA, Griggs J, Tighe CM, et al. Pharmacokinetic study of ceftazidime in bone and serum of patients undergoing hip and knee arthroplasty. *J Antimicrob Chemother* **1985**; 16:637–42.
31. Handa N, Kawakami T, Kitaoka K, et al. The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue. *Jpn J Antibiot* **1997**; 50:622–7.
32. Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B. Diffusion of cefepime into cancellous and cortical bone tissue. *J Chemother* **2003**; 15:134–8.
33. Wittmann DH, Kuipers TH, Fock R, Holl M, Bauernfeind A. Bone concentrations of imipenem after a dose of imipenem/cilastatin. *Infection* **1986**; 14(Suppl 2):S130–7.
34. MacGregor RR, Gibson GA, Bland JA. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. *Antimicrob Agents Chemother* **1986**; 29:188–92.
35. Sano T, Sakurai M, Dohi S, et al. Investigation of meropenem levels in the human bone marrow blood, bone, joint fluid and joint tissues. *Jpn J Antibiot* **1993**; 46:159–63.
36. Incavo SJ, Ronchetti PJ, Choi JH, Wu H, Kinzig M, Sorgel F. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. *Antimicrob Agents Chemother* **1994**; 38:905–7.
37. Bergogne-Berezin E. Tissue concentrations of piperacillin in humans. *Presse Med* **1986**; 15:2324–7.
38. Kato M, Morimoto R. Concentration of piperacillin in bone. *Jpn J Antibiot* **1984**; 37:279–84.
39. Foulds G, Knirsch AK, Stankewich JP, Weidler DR. The parenteral kinetics of ampicillin/sulbactam in man. *Int J Clin Pharmacol Res* **1985**; 5:79–86.
40. Wildfeuer A, Schwiersch U, Engel K, et al. Pharmacokinetics of sulbactam and ampicillin intravenously applied in combination to healthy volunteers and patients: determination of the ratio of the two drugs in serum and in various tissues. *Arzneimittelforschung* **1988**; 38:1640–3.
41. Quintiliani R, Nightingale CH. Cefazolin. *Ann Intern Med* **1978**; 89:650–6.
42. Garcia I, Fainstein V, Smith RG, Bodey GP. Multiple-dose pharmacokinetics of ceftazidime in cancer patients. *Antimicrob Agents Chemother* **1983**; 24:141–4.
43. Standiford HC, Drusano GL, Bustamante CI, et al. Imipenem co-administered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. *Antimicrob Agents Chemother* **1986**; 29:412–7.
44. Paradis D, Vallee F, Allard S, et al. Comparative study of pharmacokinetics and serum bactericidal activities of ceftiprome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. *Antimicrob Agents Chemother* **1992**; 36:2085–92.
45. Signs SA, Tan JS, Salstrom SJ, File TM. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. *Antimicrob Agents Chemother* **1992**; 36:1400–3.
46. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. *Diabet Med* **2001**; 18:229–34.
47. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. Penetration of vancomycin in uninfected sternal bone. *Antimicrob Agents Chemother* **1992**; 36:2539–41.
48. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. *Antimicrob Agents Chemother* **1994**; 38:396–9.
49. Holtom PD, Zalavras CG, Lamp KC, Park N, Friedrich LV. Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study. *Clin Orthop Relat Res* **2007**; 461:35–9.
50. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. *Antimicrob Agents Chemother* **1986**; 29:405–8.
51. Meissner A, Borner K. Concentration of ciprofloxacin in bone tissue. *Aktuelle Traumatol* **1993**; 23:80–4.
52. Wacha H, Wagner D, Schafer V, Knothe H. Concentration of ciprofloxacin in bone tissue after single parenteral administration to patients older than 70 years. *Infection* **1990**; 18:173–6.
53. von Baum H, Bottcher S, Abel R, Gerner HJ, Sonntag HG. Tissue and serum concentrations of levofloxacin in orthopaedic patients. *Int J Antimicrob Agents* **2001**; 18:335–40.
54. Rimmele T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. *J Antimicrob Chemother* **2004**; 53:533–5.
55. Fong IW, Rittenhouse BR, Simbul M, Vandenbroucke AC. Bone penetration of enoxacin in patients with and without osteomyelitis. *Antimicrob Agents Chemother* **1988**; 32:834–7.
56. Malincarne L, Ghebrezabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. *J Antimicrob Chemother* **2006**; 57:950–4.
57. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. *Antimicrob Agents Chemother* **2003**; 47:3964–6.
58. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. *J Antimicrob Chemother* **2002**; 50:73–7.
59. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. *J Antimicrob Chemother* **2002**; 50:747–50.

60. Saux MC, Le Rebeller A, Leng B, Mintrosse J. Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author's transl). *Pathol Biol (Paris)* **1982**; 30:385–8.
61. Bystedt H, Dahlbäck A, Dornbusch K, Nord CE. Concentrations of azidocillin, erythromycin, doxycycline and clindamycin in human mandibular bone. *Int J Oral Surg* **1978**; 7:442–9.
62. Dornbusch K. The detection of doxycycline activity in human bone. *Scand J Infect Dis Suppl* **1976**; 9:47–53.
63. Gnarp H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline: a clinical study. *Scand J Infect Dis Suppl* **1976**; 9:54–7.
64. Baird P, Hughes S, Sullivan M, Willmot I. Penetration into bone and tissues of clindamycin phosphate. *Postgrad Med J* **1978**; 54:65–7.
65. Nicholas P, Meyers BR, Levy RN, Hirschman SZ. Concentration of clindamycin in human bone. *Antimicrob Agents Chemother* **1975**; 8:220–1.
66. Schurman DJ, Johnson BL Jr, Finerman G, Amstutz HC. Antibiotic bone penetration: concentrations of methicillin and clindamycin phosphate in human bone taken during total hip replacement. *Clin Orthop* **1975**; 142–6.
67. Hahn F, Borner K, Koeppel P. Concentration of metronidazole in bones. *Aktuelle Traumatol* **1988**; 18:84–6.
68. Bergan T, Solhaug JH, Soreide O, Leinebo O. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. *Scand J Gastroenterol* **1985**; 20:945–50.
69. Roth B. Penetration of parenterally administered rifampicin into bone tissue. *Chemotherapy* **1984**; 30:358–65.
70. Hierholzer G, Rehn J, Knothe H, Masterson J. Antibiotic therapy of chronic post-traumatic osteomyelitis. *J Bone Joint Surg Br* **1974**; 56-B:721–9.
71. Pahle JA. Experiences with fucidin in the treatment of osteomyelitis. *Acta Orthop Scand* **1969**; 40:675.
72. Meissner A, Haag R, Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. *Infection* **1989**; 17:146–51.
73. Schintler MV, Traunmuller F, Metzler J, et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. *J Antimicrob Chemother* **2009**; 64:574–8.
74. Dudley MN, Ericson J, Zinner SH. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. *Antimicrob Agents Chemother* **1987**; 31:1782–6.
75. Burkhardt O, Borner K, von der Hoh N, et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. *J Antimicrob Chemother* **2002**; 50:707–12.
76. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. *Antimicrob Agents Chemother* **2001**; 45:1843–6.
77. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline *Ther Drug Monit* **1982**; 4:115–35.
78. Javaloyas de Morlius M, Monreal Portella M. Oral antibiotic therapy in the adult bacterial osteomyelitis: results after two years of follow-up. *Med Clin (Barc)* **1999**; 113:488–9.
79. Stein GE, Gurwith D, Gurwith M. Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections. *Antimicrob Agents Chemother* **1988**; 32:802–6.
80. Gjerloff C, Arnold E. Pharmacokinetics of intravenous metronidazole in man. *Acta Pharmacol Toxicol (Copenh)* **1982**; 51:132–5.
81. Nilsson-Ehle I, Ursing B, Nilsson-Ehle P. Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. *Antimicrob Agents Chemother* **1981**; 19:754–60.
82. Dworkin R, Modin G, Kunz S, Rich R, Zak O, Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant *Staphylococcus aureus* chronic osteomyelitis. *Antimicrob Agents Chemother* **1990**; 34:1014–16.
83. Iversen P, Nielsen OS, Jensen KM, Madsen PO. Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone. *Antimicrob Agents Chemother* **1983**; 23:338–40.
84. de Barros JW, Calapodopulos CJ, Oliveira DJ, Miki Junior P. The treatment of chronic osteomyelitis. *Rev Soc Bras Med Trop* **1992**; 25:235–9.
85. Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to *Staphylococcus aureus* with vancomycin and rifampin. *J Infect Dis* **1983**; 147:352–7.
86. Yu VL, Zuravleff JJ, Peacock JE, DeHertogh D, Tashjian L. Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of *Pseudomonas aeruginosa* infection: clinical experience with four patients. *Antimicrob Agents Chemother* **1984**; 26:575–7.
87. Zuravleff JJ, Chervenick P, Yu VL, Muder RR, Diven WF. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of *Pseudomonas aeruginosa* infections: assessment in a neutropenic mouse model. *J Lab Clin Med* **1984**; 103:878–85.
88. Chang HR, Vladioianu IR, Pechere JC. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on *Salmonella typhi* within human monocyte-derived macrophages. *J Antimicrob Chemother* **1990**; 26:689–94.
89. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate *Staphylococcus aureus*. *Pharmacotherapy* **2002**; 22:983–9.
90. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant *Staphylococcus aureus*. *J Antimicrob Chemother* **1988**; 22:873–80.
91. Burman LG. The antimicrobial activities of trimethoprim and sulfonamides. *Scand J Infect Dis* **1986**; 18:3–13.
92. Centers for Disease Control and Prevention (CDC). Outbreaks of community-associated methicillin-resistant *Staphylococcus aureus* skin infections—Los Angeles County, California, 2002–2003. *MMWR Morb Mortal Wkly Rep* **2003**; 52:88.
93. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant *Staphylococcus aureus*—an emerging problem for the management of skin and soft tissue infections. *Curr Opin Infect Dis* **2003**; 16:103–24.
94. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant *Staphylococcus aureus* infections in children. *Pediatr Infect Dis J* **2002**; 21:530–4.
95. Bancroft E, Kilgore G, Jones A, et al. Four outbreaks of community-associated methicillin-resistant *Staphylococcus aureus* in Los Angeles County. In: The 41st Annual Meeting of the Infectious Disease Society of America. San Diego, CA, **2003**.
96. Forti G, Benincori C. Doxycycline and the teeth. *Lancet* **1969**; 1:782.
97. Chazan B, Strahilevitz J, Millgram MA, Kaufmann S, Raz R. *Bacteroides fragilis* vertebral osteomyelitis secondary to anal dilatation. *Spine (Phila Pa 1976)* **2001**; 26:E377–8.
98. Riley TV, Karthigasu KT. Chronic osteomyelitis due to *Clostridium difficile*. *Br Med J (Clin Res Ed)* **1982**; 284:1217–8.
99. Melo JC, Raff MJ, Wunderlich HF, Chun CH, Summersgill JT, Varghese R. Metronidazole treatment of *Bacteroides fragilis* infections. *Am J Med Sci* **1980**; 280:143–9.
100. Zimmerman J, Silver J, Shapiro M, Friedman G, Melmed RN. Clindamycin unresponsive anaerobic osteomyelitis treated with oral metronidazole. *Scand J Infect Dis* **1980**; 12:79–80.
101. Norden CW, Fierer J, Bryant RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. *Rev Infect Dis* **1983**; 5(Suppl 3):S495–501.
102. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. *Antimicrob Agents Chemother* **1997**; 41:2670–9.

103. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. *Rev Infect Dis* **1983**; 5(Suppl 3):S428–32.
104. Reeves DS. The pharmacokinetics of fusidic acid. *J Antimicrob Chemother* **1987**; 20:467–76.
105. O'Reilly T, Kunz S, Sande E, Zak O, Sande MA, Tauber MG. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. *Antimicrob Agents Chemother* **1992**; 36:2693–7.
106. Mader JT, Reinartz JA, LeFrock JL. Cefotaxime treatment in patients with osteomyelitis and septic arthritis: a multicenter study. *Clin Ther* **1982**; 5(Suppl A):10–8.
107. LeFrock JL, Carr BB. Clinical experience with cefotaxime in the treatment of serious bone and joint infections. *Rev Infect Dis* **1982**; 4(Suppl):S465–71.
108. MacGregor RR, Gentry LO. Imipenem/cilastatin in the treatment of osteomyelitis. *Am J Med* **1985**; 78:100–3.
109. Bach MC, Cocchetto DM. Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis. *Antimicrob Agents Chemother* **1987**; 31:1605–8.
110. Gomis M, Herranz A, Aparicio P, Filloy JL, Pastor J. Cefotaxime in the treatment of chronic osteomyelitis caused by gram-negative bacilli. *J Antimicrob Chemother* **1990**; 26(Suppl A):45–52.
111. Simons WJ, Lee TJ. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. *Rev Infect Dis* **1985**; 7(Suppl 4):S783–8.
112. Conrad DA, Williams RR, Couchman TL, Lentnek AL. Efficacy of aztreonam in the treatment of skeletal infections due to *Pseudomonas aeruginosa*. *Rev Infect Dis* **1991**; 13(Suppl 7):S634–9.
113. Lucht RF, Fresard A, Berthelot P, et al. Prolonged treatment of chronic *Pseudomonas aeruginosa* osteomyelitis with a combination of two effective antibiotics. *Infection* **1994**; 22:276–80.
114. Akova M, Ozcebe O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. *J Chemother* **1996**; 8:284–9.
115. Munckhof WJ, Carney J, Neilson G, et al. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. *Int J Antimicrob Agents* **2005**; 25:514–22.
116. Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by gram-negative bacilli with a cefepime-fluoroquinolone combination. *Clin Microbiol Infect* **2006**; 12:1030–3.
117. Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant *Staphylococcus aureus* infections. *J Infect* **2008**; 57:110–5.
118. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC Jr, Musher DM. Outcomes of treatment for hematogenous *Staphylococcus aureus* vertebral osteomyelitis in the MRSA ERA. *J Infect* **2008**; 57:128–31.
119. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. *Curr Med Res Opin* **2005**; 21:1923–6.
120. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. *Am J Med* **2007**; 120(10 Suppl 1):S13–20.
121. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. *Am J Med* **2003**; 114:723–8.
122. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. *J Antimicrob Chemother* **2003**; 51:1261–8.
123. Schafer JJ, Mangino JE. Multidrug-resistant *Acinetobacter baumannii* osteomyelitis from Iraq. *Emerg Infect Dis* **2008**; 14:512–4.
124. Chen PL, Yan JJ, Wu CJ, et al. Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* **2010**; 68:312–4.
125. Kuo SC, Wang FD, Fung CP, et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. *J Microbiol Immunol Infect* **2011**; 44:45–51.
126. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. *J Antimicrob Chemother* **2004**; 53:928–35.
127. Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections: efficacy, safety, and pharmacokinetics. *Am J Med* **1987**; 82:146–53.
128. Lesse AJ, Freer C, Salata RA, Francis JB, Scheld WM. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. *Am J Med* **1987**; 82:247–53.
129. Gilbert DN, Tice AD, Marsh PK, Craven PC, Preheim LC. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. *Am J Med* **1987**; 82:254–8.
130. Hessen MT, Ingerman MJ, Kaufman DH, et al. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. *Am J Med* **1987**; 82:262–5.
131. Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. *Antimicrob Agents Chemother* **1987**; 31:151–5.
132. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. *J Bone Joint Surg Am* **1990**; 72:104–10.
133. Giamarellou H, Galanakis N. Use of intravenous ciprofloxacin in difficult-to-treat infections. *Am J Med* **1987**; 82:346–51.
134. Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. *Am J Med* **1987**; 82:369–75.
135. Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin: report from a Swedish Study Group. *J Antimicrob Chemother* **1988**; 22:221–8.
136. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. *Antimicrob Agents Chemother* **2000**; 44:164–6.
137. Dellamonica P, Bernard E, Etesse H, Garraffo R, Drugeon HB. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. *Eur J Clin Microbiol Infect Dis* **1989**; 8:1024–30.
138. Ketterl R, Beckurts T, Stubinger B, Claudi B. Use of ofloxacin in open fractures and in the treatment of post-traumatic osteomyelitis. *J Antimicrob Chemother* **1988**; 22(Suppl C):159–66.
139. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. *Am J Med* **1989**; 86:801–8.
140. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of *Staphylococcus*-infected orthopedic implants. *Antimicrob Agents Chemother* **1993**; 37:1214–8.
141. Barberan J, Aguilar L, Gimenez MJ, Carroquino G, Granizo JJ, Prieto J. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. *Int J Antimicrob Agents* **2008**; 32:154–7.
142. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of *Staphylococcus* spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. *J Antimicrob Chemother* **1997**; 39:235–40.
143. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. *Clin Infect Dis* **2011**; 53:334–40.
144. El Helou OC, Barbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. *Eur J Clin Microbiol Infect Dis* **2010**; 29:961–7.
145. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. *Clin Infect Dis* **2003**; 36:159–68.

146. Pontifex AH, McNaught DR. The treatment of chronic osteomyelitis with clindamycin. *Can Med Assoc J* **1973**; 109:105–7.
147. Craven JL, Pugsley DJ, Blowers R. Trimethoprim-sulphamethoxazole in acute osteomyelitis due to penicillin-resistant staphylococci in Uganda. *Br Med J* **1970**; 3:201–3.
148. Saengnipanthkul S, Pongvivat T, Mahaisavariya B, Laupattarakasem W. Co-trimoxazole in the treatment of chronic osteomyelitis. *J Med Assoc Thai* **1988**; 71:186–91.
149. Sanchez C, Matamala A, Salavert M, et al. Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection. *Enferm Infecc Microbiol Clin* **1997**; 15:10–3.
150. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant *Staphylococcus*-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). *Antimicrob Agents Chemother* **1998**; 42:3086–91.
151. Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. *Clin Microbiol Infect* **2009**; 15:1163–9.
152. Fernandez-Valencia JE, Saban T, Canedo T, Olay T. Fosfomycin in osteomyelitis. *Chemotherapy* **1976**; 22:121–34.
153. Papasian CJ, McGregor DH, Hodges GR, Kennedy J. Peptostreptococcal vertebral osteomyelitis. *J Clin Microbiol* **1986**; 24:633–5.
154. Seto BG, Lynch SR, Moy PK. Chronic osteomyelitis of mandible caused by penicillin-resistant *Bacteroides ruminicola*. Report of a case. *Oral Surg Oral Med Oral Pathol* **1986**; 61:29–31.
155. Edmondson HT. Parenteral and oral clindamycin therapy in surgical infections: a preliminary report. *Ann Surg* **1973**; 178:637–42.
156. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. *Int J Antimicrob Agents* **1999**; 12(Suppl 2):S79–93.
157. Wolfe CR. Case report: treatment of chronic osteomyelitis. *Clin Infect Dis* **2011**; 52(Suppl 7):S538–41.
158. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. *Cochrane Database Syst Rev* **2009**; (3):CD004439.
159. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. *Antimicrob Agents Chemother* **1985**; 28:467–72.
160. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by *Staphylococcus aureus*: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. *South Med J* **1986**; 79:947–51.
161. Sheftel TG, Mader JT. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. *Antimicrob Agents Chemother* **1986**; 29:112–5.
162. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. *Clin Infect Dis* **2004**; 38:17–24.
163. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *Foreign-Body Infection (FBI) Study Group. JAMA* **1998**; 279:1537–41.
164. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. *Am J Med* **1987**; 82:266–9.
165. Peacock JE Jr, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. *Am J Med* **1989**; 87:185S–90S.
166. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. *Antimicrob Agents Chemother* **1990**; 34:40–3.
167. Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. *Antimicrob Agents Chemother* **1991**; 35:538–41.
168. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. *Clin Infect Dis* **1997**; 24:643–8.
169. Gomis M, Barberan J, Sanchez B, Khorrani S, Borja J, Garcia-Barbal J. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. *Rev Esp Quimioter* **1999**; 12:244–9.
170. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. *Antimicrob Agents Chemother* **2009**; 53:2672–6.
171. Schmitz FJ, Fluit AC, Hafner D, et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant *Staphylococcus aureus* isolates. *Antimicrob Agents Chemother* **2000**; 44:3229–31.
172. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. *Clin Infect Dis* **2004**; 38:864–70.